Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
86,559,040
-
Total 13F shares
-
71,468,832
-
Share change
-
+10,250,881
-
Total reported value
-
$1,818,847,118
-
Put/Call ratio
-
96%
-
Price per share
-
$25.45
-
Number of holders
-
159
-
Value change
-
+$262,720,878
-
Number of buys
-
96
-
Number of sells
-
47
Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) as of Q4 2022
As of 31 Dec 2022,
Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
71,468,832 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Avidity Partners Management LP, BlackRock Inc., Frazier Life Sciences Management, L.P., STATE STREET CORP, VANGUARD GROUP INC, Avoro Capital Advisors LLC, Kynam Capital Management, LP, JENNISON ASSOCIATES LLC, and ORBIMED ADVISORS LLC.
This page lists
159
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.